The FDA's controversial approval of a Biogen drug for Alzheimer's disease could blunt future R&D, experts warn.
The New Alzheimer's Drug Is the First of its Kind
Comment
Show comments
Hide Comments
The FDA's controversial approval of a Biogen drug for Alzheimer's disease could blunt future R&D, experts warn.
